The combination of gemcitabine/erlotinib/DIM could more effectively inhibit pancreatic cancer cell lines that highly express EGFR, NF-κB, and COX2 than any one of the three agents both in vivo and in vitro63. This evidence concerns the gene EGFR and pancreatic neoplasm.